test of the scalability of this local growth factor treatment. Spontaneous perfusion recovery diminished with increasing age, and only the combination of VEGF and IGF delivery from gels significantly rescued perfusion in middle-aged (13 months) and old (20 months) mice. In rabbits, the delivery of VEGF alone or in combination with IGF from alginate hydrogels, at a dose 2 orders of magnitude lower than the typical doses used in past rabbit studies, enhanced perfusion recovery when given immediately after surgery, or as a treatment for chronic ischemia. Capillary density measurements and angiographic analysis demonstrated the benefit of gel delivery. These data together suggest that alginate hydrogels providing local delivery of low doses of VEGF and IGF constitute a safe and effective treatment for hind-limb ischemia in clinically relevant animal models, thereby supporting the potential clinical translation of this concept.
Introduction
Peripheral artery disease (PAD) affects nearly 30 million people, and can lead to limb amputation [1, 2] . Therapeutic angiogenesis offers an alternative treatment strategy to traditional medical and surgical interventions, and consists of promoting new blood vessel formation from preexisting vessels [3] . Individual angiogenic proteins, such as vascular endothelial growth factor (VEGF), have been delivered via systemic administration to drive angiogenesis. However, large clinical trials using recombinant protein delivery have, to date, not demonstrated a significant benefit [4, 5] . Bolus delivery strategies are limited due to the inherent instability of these proteins in vivo (e.g., a short half-life following intravenous infusion) [6, 7] and inadequate targeting to the tissue of interest [8] . Ischemic tissues require an extended time period of exposure to these factors to initiate and complete the angiogenic process [9] . The delivery of large protein doses to overcome the rapid degradation is constrained by the possibility of serious side effects at distant sites, and systemic injection of angiogenic proteins has largely been abandoned due to the risks associated with the required large doses [10] . Gene and cell delivery therapies may bypass these limitations, but phase 3 trials for plasmid and DNA delivery have not provided compelling data of patient benefits, and the efficacy of cell therapies remains to be validated in large, randomized trials [10] [11] [12] [13] [14] [15] [16] [17] . Altogether, the results to date from therapeutic angiogenesis studies suggest that the efficacy of single-molecule therapies is likely to be limited, and the time frame and spatial distribution of any therapeutic agent is likely to be critical to its efficacy [8] .
To address the limitations confronted in clinical trials to date, we previously developed biomaterials that allow angiogenic factors, such as VEGF, to be localized to the tissue of interest and to have improved pharmacokinetic profiles [18, 19] . In particular, alginate hydrogels are considered biocompatible, can be modified to alter the degradation profile, and can be processed into formulations allowing minimally invasive delivery [20] [21] [22] . An injectable alginate gel formulation, comprising a combination of high-and low-molecular-weight alginate polymers, both oxidized to 1%, and mixed with VEGF, was found to effectively restore perfusion in mouse models of hindlimb ischemia by inducing angiogenesis [22, 23] . Additionally, incorporating insulin-like growth factor (IGF) along with VEGF improved the recovery of muscle strength following the induction of hind-limb ischemia in this mouse model [24] . We have repeatedly demonstrated that the use of alginate gel materials loaded with growth factors constitutes a safe, reliable, and effective approach for the treatment of hind-limb ischemia in rodent models.
In this study, we investigated the impact on perfusion recovery of the local delivery of VEGF and IGF from injectable alginate in 2 animal models (young rabbits and old mice) of PAD, both relevant for the clinical translation of this concept. Past studies were performed in mice aged approximately 8-10 weeks, which are equivalent to human teenagers [25] . In contrast, the age of various patient cohorts in large therapeutic angiogenesis clinical trials (e.g., VIVA, TRAFFIC, RAVE, and NVIFGF) ranged from 58 ± 8 to 72 ± 10 years old [4, [26] [27] [28] . Mapping of human to mouse age indicates that a 70-year-old human with arteriopathy would correlate with a 500-day-old mouse [25] . In addition, humans are approximately 3,000 times bigger than a mouse, raising significant concerns regarding the scaling of the gel-based delivery of angiogenic factors. Testing this system in a rabbit model provides a significant test of the scalability of the concept, as rabbits are approximately 100-fold larger than mice, and only 30-fold smaller than humans. As concerns arose in human clinical trials regarding high systemic concentrations of VEGF, the dose of VEGF for this local therapy was scaled to the volume of the treatment region in the hind limb, and so it is significantly reduced when compared to dose-scaling based on whole-body mass which is typically used for systemically administered drugs. In taking steps towards completing important preclinical development for this therapeutic angiogenesis strategy, these studies illustrate the therapeutic efficacy of VEGF and IGF delivered locally from alginate in 2 clinically relevant models of hind-limb ischemia.
Methods
See the online supplementary material for extended methods (www.karger.com/doi/10.1159/000479869).
Alginate Gels
Alginate gels were prepared from a mix of high-and low-molecular-weight ultrapure alginates (Pronova MVG #4200106 and VLVG #4200506, respectively) [22] . Gels were cross-linked with CaSO 4 and injected approximately 1 h after preparation.
In vivo Gel Degradation
Fluorescently labeled alginate gel was injected into the hindlimb muscle of mice ( n = 4). Mice were imaged with an in vivo imaging system (Perkin Elmer) at various time points. All mouse protocols followed institutional guidelines set by the Harvard University IACUC.
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Mouse Hind-Limb Ischemia Model and Blood Vessel Analysis
Hind-limb ischemia was induced in female C57BL6/J mice as previously described [19, 22, 23] , and was followed immediately by an intramuscular injection of 50 μL of alginate gel containing 3 μg of each of VEGF and IGF (R&D Systems #293-VE/CF and #291-G1, respectively), VEGF only, IGF only, or no growth factors (control condition), given directly into the area where the vessels were ligated ( n = 4-6). Mice were monitored by laser Doppler perfusion imaging (LDPI), and capillary density was quantified by staining for mouse CD31 (BD Biosciences #557355) [22, 23] .
Rabbit Hind-Limb Ischemia Model and Blood Vessel Analysis
All rabbit procedures followed institutional guidelines set by the University of Michigan IACUC. Ischemia was induced in female NZ White rabbits (body weight: 2.5-3 kg) by ligation of the lateral circumflex artery, and the common, superficial, and deep femoral arteries. Ten 50-μL injections of alginate gel, in total containing 20 μg of each growth factor (VEGF + IGF, VEGF only, or VEGF + IGF in saline) were then delivered in 2 rows of 5 evenly spaced locations surrounding the ligation site. A PDMS-based mold was used as a guide to ensure even spacing of injections and consistency between animals. Control rabbits were given no treatment. For 1 condition, rabbits were given no treatment initially, but were then treated with gels containing VEGF + IGF on day 30, via percutaneous injection ( n = 6). Rabbits were monitored by LDPI. Blood vessels were stained using an antibody to CD31 (Abcam #ab9498) and were quantified ( n = 6-9 for all groups).
Angiography
Angiography was performed on 1 rabbit/treatment group on day 28. Contrast medium was manually injected via a catheter proximal to the branch point of the common iliac arteries. Serial images were then recorded, and the image representing the best arterial filling was chosen for analysis. The length of the hypogastric artery and all whole, visible, collateral branches were measured.
Statistical Analysis
All data were compared using either the Student t test or a oneway ANOVA with the Tukey post hoc test. p < 0.05 was considered statistically significant.
Results

Hind-Limb Ischemia Recovery Variation with Age
Spontaneous recovery in young, middle-aged, and old mice that underwent hind-limb ischemia surgery was monitored over time. Middle-aged (13 months) and old (20 months) mice were chosen to bracket the average age of patients in the therapeutic angiogenesis clinical trials (a 70-year-old human with arteriopathy is equivalent to a 17-month-old mouse) [25] [26] [27] [28] . Only 20% of the young mice displayed any necrosis ( Fig. 1 a) . The middle-aged mice displayed increased necrosis and the old mice exhibited significant necrosis of the foot. Altered cytokine levels may impair regeneration, and middle-aged mice displayed lower levels of IGF-binding proteins 1 and 9 and matrix metalloproteinase 9 than the young animals ( Fig. 1 b; online suppl. Fig. S1 ). Alginate Gels Alginate polymers were made into an injectable formulation by combining 1% oxidized, low-and high-molecular-weight polymers in a 75: 25 ratio ( Fig. 2 a) . The viscosity of the solution was sufficiently low to allow the gel to be injected after cross-linking with CaSO 4 ( Fig. 2 b) . Oxidation of the polymer backbone allows hydrolytic degradation of the polymer backbone [29] . The high-molecular-weight polymer component degraded from 233 to 117 kDa, and the low-molecular-weight polymer degraded from 31 to 25 kDa over approximately 1 week in physiological saline solution at 37 ° C. In vivo, alginate gels were lost from the injection site in mice over a few months ( Fig. 2 c) . The VEGF-and IGF-release kinetics from these gels were established previously [22, 24] .
Effect of VEGF/IGF Treatment in Aged Mice
As angiogenic and overall regenerative capacity decreases with age, supplementation with exogenously delivered factors may be increasingly important to improve healing outcomes. Alginate gels loaded with VEGF and IGF were tested for their ability to drive neovascularization and muscle-tissue regeneration following hind-limb ischemia surgery in old animals, as this growth factor combination was previously found to be effective in young animals [24] . IGF supplementation may be especially important in aged mice, because the decreased levels of IGF-binding proteins leaves IGF unprotected and results in a shortened half-life [30] . Old animals treated with alginate gels delivering both VEGF and IGF displayed a 2-fold increase in the regional blood flow compared to with the blank gel ( Fig. 3 a) , while no statistical differences were found for animals which received either VEGF or IGF only. These trends were replicated in the ischemia scores (online suppl. Fig. S2a ). However, all 3 treatment groups showed increased capillary density than the mice which received the blank gel ( Fig. 3 b) . Furthermore, measurements of muscle strength were highest in the mice treated with a combination of VEGF and IGF (online suppl. Fig. S2b ). Increased doses of VEGF (2× and 4×) were also tested to determine if the poor outcome in old mice was simply a result of a decreased sensitivity to VEGF, but these higher doses did not increase blood flow (online suppl. Fig. S2c) . Previous studies have repeatedly demonstrated no impact of the bolus delivery of these factors, at these doses, on perfusion recovery in this model [22, 24, 31] , and so were not repeated here (to minimize animal experimentation).
Middle-aged animals were next subjected to hindlimb ischemia surgery and were treated with either blank gel, gel loaded with VEGF, or gel loaded with VEGF and IGF, as gels with IGF alone do not improve perfusion recovery in young [24] or old animals. Mice treated with the gels containing VEGF only and VEGF + IGF displayed a prominent increase in perfusion compared to the blank gels ( Fig. 3 c) . The VEGF + IGF treatment was close to presurgery levels (approx. 90%), and led to greater perfusion than VEGF only. The density of blood vessels was increased in both treatment groups ( Fig. 3 d) . Importantly, as the stability of vessels formed with angiogenic factor treatment has been raised as an issue [32, 33] , the mice were analyzed for 90 days posttreatment in these studies and a stable reperfusion was noted. While past studies have typically examined perfusion for time periods ranging from 7 to 42 days, our extended monitoring demonstrates that a stable reperfusion was established with these factors and this mode of delivery.
Hind-Limb Ischemia Treatment in Young Rabbits
Standardized processes for the alginate polymer modification and gel material fabrication were developed for the rabbit studies, and the gels and growth factors were packaged into a standardized kit in order to maintain consistency across studies (online suppl. Fig. S3 ). Experimental conditions included control, bolus VEGF + IGF, alginate loaded with VEGF and alginate loaded with VEGF + IGF. In contrast to the mouse studies, the mouse studies, also in an effort to minimize the number of animals, alginate gels loaded with IGF only were not used here (rabbit studies), as this condition has been shown to be ineffective in restoring blood profusion in murine hind-limb ischemia [24] . The bolus injection of VEGF + IGF was included to validate if the gel-based delivery was superior to the bolus delivery in this species (not shown before). In addition, the chosen dose of VEGF and IGF (20 μg each) was much lower than previous VEGF doses used for the treatment of ischemia in rabbits, mini-swine, and in human clinical trials ( Table 1 ; online suppl. Table  S1 ). Gel injection into ischemic limbs did not result in any detectable systemic exposure ( Fig. 4 a) , consistent with previous rodent studies [22] . This contrasts with delivery approaches in past clinical studies, where large quantities of potent factors were present in the systemic circulation [4, 7] . LDPI ( Fig. 4 b) revealed that perfusion in the ischemic limb was reduced to approximately 5% immediately after surgery ( Fig. 4 c) . Without treatment, perfusion recovered to approximately 50% within around 1 week, and then remained stable. However, immediate treatment with alginate gels (a total dose of 20 μg of VEGF or VEGF and IGF) led to a significant improvement in perfusion, which reached 80-90% of the level in the healthy, contralateral limb, and was maintained throughout the 7-week monitoring period. Quantification of capillary density at 7 weeks revealed a slight increase with the VEGF treatment and a statistically significant increase with VEGF + IGF treatment compared to the control condition ( Fig. 4 d, e ; online suppl. Fig. S4 ). Treatment with VEGF and with VEGF + IGF also positively impacted muscle-fiber size ( Fig. 4 f) and the number of blood vessels/muscle fiber ( Fig. 4 g) , with the combination treatment demonstrating the greater effect. Bolus delivery of VEGF + IGF was used as a control, and no impact on perfusion or capillary density was found ( Fig. 4 b-g ).
Delayed Treatment
As a model of chronic ischemia, 1 rabbit cohort was only treated on day 30, after perfusion had stabilized to approximately 50%. Percutaneous injections were used to deliver gels into the muscle tissue surrounding the vessel ligation site, with the same factor doses as used for the acute treatment ( Fig. 5 a) . The combination of VEGF + IGF increased perfusion significantly within 14 days after the injection, which was the same amount of time required for significant differences to be observed with the acute treatment ( Fig. 5 b) . Perfusion subsequently increased to the same level as in rabbits treated immediately with VEGF or with VEGF + IGF. Rabbits receiving a delayed treatment also displayed a higher capillary density (126 ± 29 blood vessels/mm 2 ) than the control rabbits.
Angiographic Observations
Angiographic imaging was performed on 1 animal in each of the gel treatment groups and in the control group. Since no difference in perfusion was observed with bolus delivery of VEGF + IGF, that condition was not analyzed. Extensive collateral formation was found in the ischemic limb for all conditions ( Fig. 6 a, b) . Delivery of VEGF + IGF from alginate gels resulted in more extensive collateral vessels, which appeared to reconstitute the superficial femoral artery distal to the ligation site more briskly and fully ( Fig. 6 a) . The hypogastric artery appeared to be the major collateral donor vessel. Measurement of the total length of the hypogastric artery and its branches, normalized to vessel length in the contralateral limb, and the total number of collateral branches in the ischemic limb, revealed that treatment with VEGF and IGF increased the formation of angiographically visible collateral vessels ( Fig. 6 b; online suppl. Fig. S5 ).
Discussion
These experiments demonstrated that treatment with low doses of VEGF and IGF delivered locally from injectable alginate hydrogels results in significant and stable increases in tissue perfusion in a young rabbit model of hind-limb ischemia and in aged mice. Delivery of IGF in combination with VEGF can offset the diminished response to VEGF with age. In young rabbits, immediate treatment with alginate gels loaded with VEGF and with a combination of VEGF + IGF similarly improved perfusion and capillary density. Alginate gel-based delivery also effectively treated chronic ischemia, and appears to provide a safe and effective means for local angiogenic factor delivery. The old mice and the young rabbits had some differences in response to the delivery of growth factors, and these effects likely relate to both the species and age differences. However, the robust response to alginate gel delivery of VEGF in young mice in previous studies [22] suggests that the differences mainly result from the age difference in this study between the 2 models. What is important to note, though, is that the delivery of VEGF and IGF from alginate gels resulted in significantly improved perfusion recovery in both of these relevant animal models. Alginate gel-based growth factor delivery led to both angiogenesis and arteriogenesis in muscles surrounding the injection site, and both likely contributed to the beneficial effects on perfusion.
Recovery from ischemia is a complex, multistep process, and the ability of individuals to recover weakens with age [34] . While most angiogenesis studies using rodent models are done on young mice [23, 24] , naturally, aged mice do not recover as well as young mice, similar to the human condition. In young mice, treatment with VEGF only effectively restores perfusion [22] [23] [24] , but in old mice, even large doses of VEGF did not promote significant healing. This result may partially explain the poor results in human clinical trials in which VEGF was infused as a stand-alone therapy. The delivery of a combination of VEGF + IGF gel, in contrast, was found to improve perfusion, capillary density, and muscle strength, and also prevented significant necrosis. IGF plays a key role in embryonic and postnatal growth and metabolism [35] , muscle regeneration [36] , and the regulation of angiogenesis and vascular remodeling [37, 38] . The aging process is associated with a significant reduction in the levels of circulating IGF [39] , possibly due to lower IGFbinding protein levels [30] , and corresponding decreases in capillary density are also associated with age-related decreases in IGF [40] . Our results and past works together suggest that the delivery of IGF in combination with VEGF can help to overcome healing impediments in aged individuals and restore perfusion to ischemic limbs. c Quantification of perfusion recovery after hind-limb ischemia surgery ( n = 6-9). * p < 0.05 compared to control condition for both VEGF and VEGF + IGF. A rabbit hind-limb ischemia model was also used as a rigorous test of the scalability of our alginate-based, local growth factor delivery system. Delivery of VEGF + IGF or VEGF only from the gels resulted in improved perfusion recovery, while a direct bolus injection of VEGF + IGF did not augment perfusion. The enhanced perfusion was reflected in histologic measurements of capillary density, and digitally subtracted angiograms revealed that treatment with the combination of VEGF + IGF, and, to a lesser extent, VEGF only, also led to larger and more numerous angiographically visible collateral arteries. The reconstitution of an occluded artery by collateral arteries is thought to be clinically relevant for humans with severe PAD, further supporting the use of VEGF and IGF together in future clinical applications. In these young rabbits, VEGF performed nearly as well as the combination of VEGF and IGF, but it is likely that aged rabbits would exhibit a similar diminished healing ability as was shown in the mice; such studies are beyond the scope of this report due to practical time limitations. In translating the aged mice results to aged rabbits, and later to humans, the combination of VEGF and IGF would be expected to augment perfusion and overall regeneration more effectively than using VEGF as a single-molecule therapy.
Local delivery of VEGF and IGF from the gels also restored perfusion to rabbit limbs that displayed stable, chronic ischemia. By day 30 after permanent ligation of the femoral artery tree, acute inflammation and immune cell infiltration are expected to have subsided [41, 42] . While untreated animals displayed a permanent reduction in perfusion which persisted until the end of the experiment, the rabbits that were treated on day 30 recovered to the same level as the rabbits treated acutely. To our knowledge, this is the first demonstration of a significantly delayed therapeutic intervention following ischemic injury. This is particularly relevant to the human condi- tion, as a slow narrowing of vessels due to atherosclerotic plaque formation characterizes ischemic cardiovascular and peripheral vascular diseases, and the onset of PAD often goes unnoticed until the disease has progressed to the severe stages, when patients experience classic claudication and face threats of limb amputation due to critical limb ischemia [43] . Finally, the use of alginate hydrogels to deliver VEGF and IGF is more effective, and likely safer, than systemic infusions or bolus injections of growth factors. In these studies, the growth factor dose was not scaled from previous successful mouse studies based on weight, but instead by the volume of the treatment region. Rabbits are 100 times the size of a mouse, but a much lower dose of VEGF and IGF (approx. 6.5× the mouse dose) effectively restored perfusion. Previous rabbit studies that employed intracoronary, intravascular, or intramuscular injections to deliver a bolus of VEGF were able to augment collateral growth and capillary density, but required doses that were 25-500 times larger than the dose used here ( Table 1 ; online suppl. Table S1 ). Scaling our rabbit dose to humans based on weight suggests that delivering approximately 20% of the maximum tolerated VEGF dose (determined from systemic delivery in previous human clinical trials [44] ) should be effective when this alginate gel delivery system is utilized. These studies also demonstrate that containing the growth factors within the gel and delivering the gel directly to the target tissue lead to a minimal impact in the systemic circulation, which is expected to contribute to the safety of this system. In summary, these data together suggest that the local delivery of VEGF and IGF from injectable alginate hydrogels would be a viable treatment option for PAD, which can address the specific limitations and overcome the significant challenges faced by alternative therapeutic angiogenesis treatment strategies.
